Drugs / Ohtuvayre
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OHTUVAYRE | — | 2024-06-26 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07331402 | Jul → Dec 2025 overdue | chronic obstructive pulmonary disease | Haisco Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ohtuvayre | “Ohtuvayre inhalation suspension” NCT07331402 ↗ |
| Route | Inhaled | “Inhale through the mouth” NCT07331402 ↗ |